Found’s lowest advertised price is not a complete answer to what you will pay. The online weight-management program sells several distinct arrangements: compounded medication bundled with care and membership, branded prescribing support with medication billed separately, and a non-GLP-1 generics plan. Insurance can change the care price without covering the compounded drug itself. Meanwhile, some advertised minimums depend on a prepaid 12-month plan, while the offer terms describe four-week billing cycles.
This documentary review examines Found’s public pricing, billing consent, medication pages and offer terms consulted October 19, 2026. The central budgeting question is not simply whether Found is affordable, but which service, medication, payment schedule and renewal price your checkout actually buys. Found documents substantial care and support features, but its pages leave meaningful differences unresolved—including how prepayment works, how Medicare fits its general insurance exclusions, and why branded-drug prices differ between pages.
At a glance
- Compounded semaglutide pricing
- Published plan rates range from $99 to $199 with insurance and $169 to $289 cash pay, depending on term, per 28-day cycle. The commercial page ties minimum advertised pricing to 12-month plans paid upfront.
- Compounded tirzepatide pricing
- Published plan rates range from $179 to $289 with insurance and $239 to $359 cash pay, depending on term, per 28-day cycle; new-member one-month discounts have separate renewal prices.Sources: [7]
- Branded medication costs extra
- The branded GLP-1 plan includes prescription services and membership, not the medication. Published membership rates range from $49 to $89 with insurance and $99 to $149 cash pay per 28-day cycle.Sources: [7]
- Insurance does not cover every component
- Found’s consent makes patients responsible for compounded GLP-1 charges and treats the subscription as a noncovered service. Insured video visits generally add a copay described as around $30.
- Renewal and refund boundaries
- Renewal payments are nonrefundable. Found recommends canceling or pausing at least 48 hours before renewal; medications and lab kits cannot be returned or refunded once dispensed or shipped.Sources: [7]
Start with the first charge—not the smallest headline
Found’s one-month introductory offers make the first payment look different from the ongoing bill. For new members choosing that term, compounded semaglutide is $99 initially with insurance, then $199 per cycle; cash pay is $179 initially, then $289. Compounded tirzepatide is $149 initially with insurance, then $289; cash pay is $219 initially, then $359. These are explicitly introductory discounts, not continuing rates. The terms describe billing every four weeks, despite using “month” in the price labels.
Separate promotions apply to membership supporting branded prescriptions. Found advertises $100 off the initial cash-pay membership checkout, including plans supporting Zepbound vials, Wegovy pens and Wegovy pills, and $50 off the initial checkout when Found is in-network with insurance. These offers exclude Med Kit plans, are limited to one redemption per account and can change. They do not establish a discount on every subsequent medication purchase or membership renewal.
The lowest longer-term prices require another distinction. Found’s commercial page says its starting prices are based on 12-month plans paid upfront, while its terms describe rates billed every 28 days. Those statements do not clearly establish the amount collected at checkout or the number of later charges for every option. Before paying, request both figures in writing. Our guide to why the first payment can differ from the advertised price explains how to separate a checkout discount from a recurring rate.
| Plan and payment route | First advertised month | Subsequent advertised rate |
|---|---|---|
| Compounded semaglutide, with insurance | $99 | $199 per 28-day cycle |
| Compounded semaglutide, cash pay | $179 | $289 per 28-day cycle |
| Compounded tirzepatide, with insurance | $149 | $289 per 28-day cycle |
| Compounded tirzepatide, cash pay | $219 | $359 per 28-day cycle |
Longer terms reduce the quoted rate, but need a clearer payment schedule
For compounded semaglutide, Found lists one-, three-, six- and 12-month rates of $199, $159, $129 and $99 with insurance, respectively. Cash-pay rates for those same terms are $289, $249, $219 and $169. The terms say these prices include clinical care, compounded medication and membership, with billing every four weeks. They are not quotes for branded semaglutide, and the insurance column does not mean the compounded medication is an insured benefit.
Compounded tirzepatide follows the same term structure but has different prices: $289, $239, $209 and $179 with insurance; $359, $309, $289 and $239 cash pay. The published package includes clinical care, medication and membership. Lower quoted rates therefore reflect a different plan selection, not simply a cheaper version of the one-month arrangement. Applicable laboratory testing remains outside the compounded package, and insured care can produce additional cost-sharing.
The calendar deserves special attention. Found’s generic and branded membership tables expressly translate their terms into four, 12, 24 and 48 weeks. Twelve 28-day cycles are 48 weeks, not a calendar year. A package label also does not independently establish medication quantity or a minimum commitment. The unresolved upfront-versus-recurring language makes a written schedule especially valuable; see four-week and prepaid billing explained before comparing these prices with calendar-month subscriptions.
Branded prescribing support is not a medication bundle
Found’s branded GLP-1 membership costs $89, $79, $69 or $49 with insurance for the one-, three-, six- or 12-month terms. Cash-pay membership is $149, $139, $129 or $99 for those terms, billed every 28 days. Unlike the compounded plan, this includes prescription services and membership but excludes the drug. Found’s non-GLP-1 oral generics plan has the same published rate schedule, but includes prescription services, medication and membership—a material difference despite matching prices.
The drug catalog separately advertises Ozempic at $1,100 per month, Wegovy from $650 per month or more, Zepbound from $650 per month or more, and Mounjaro at approximately $1,100 per month. That block does not fully specify supply quantities or purchase conditions. Other comparison material gives Wegovy figures of $149–$349 per month and Zepbound figures of $299–$449, subject to cash-pay and multimonth conditions. The consulted material does not reconcile presentation, promotion or channel differences.
For branded prescriptions, Found says members may use their chosen pharmacy, paying cash or using insurance, or access NovoCare or LillyDirect when eligible. Found describes those latter channels as cash-pay only. A useful quote therefore identifies the exact product, presentation, pharmacy route, membership charge and medication charge—not just the drug name. The difference between a membership discount and a pharmacy price is central to understanding separate program and pharmacy bills.
“With insurance” changes the care bill, not every expense
Found’s insurance pricing reflects coverage for clinical care, according to its terms. Its billing consent separately says members are financially responsible for compounded GLP-1 charges and may not submit those amounts to their health plan. It also identifies the Found subscription as a noncovered service. These distinctions matter because an insurance-associated package price can otherwise sound like evidence that the insurer pays for the compounded medication. The documents say otherwise.
The visit process also affects cost. With insurance, Found requires synchronous video visits, including before each refill, and bills those visits through insurance at the member’s visit copay—described as typically around $30—on top of the plan price. Coinsurance and deductibles may also apply. Cash-pay care is text-based and asynchronous in most cases, with no separate visit copay. These are different service and billing arrangements, not merely two prices for an identical encounter format.
Found offers a free coverage checker that reports medication-specific coverage, prior-authorization requirements and estimated copays or out-of-pocket expenses when available. It does not itself request treatment or issue a prescription. Later claim processing can still generate a bill: the consent gives 15 days to pay a post-claim invoice before charging the stored card. If payment fails, it allows another 30 days to resolve the balance before subscription termination. A scheduled consultation missed or canceled with less than 24 hours’ notice carries a $30 fee.
Medicare needs its own written explanation
Found’s general offer terms exclude people with government insurance—including Medicare, Medicaid, TriCare and MediCal—from the insurance-price offer. A separate page nevertheless advertises care for adults ages 65–75 and conditional access to what Found calls the Medicare GLP-1 Bridge. These statements should not be flattened into either universal Medicare acceptance or a universal refusal. The reviewed pages do not fully explain which membership, clinical billing and medication arrangements apply together.
According to Found’s Medicare page, the Bridge runs July 1, 2026, through December 31, 2027, outside the ordinary Part D payment flow. It describes a $50 monthly medication copay for eligible Part D members with qualifying weight-management prescriptions, separate from Found membership. Found says eligibility is not guaranteed, the copay does not count toward the Part D deductible or out-of-pocket maximum, and low-income subsidies, including Extra Help, do not apply.
That page lists Wegovy injections and tablets, Zepbound KwikPen and Foundayo, while noting that Medicare may update the list. It also advertises compounded semaglutide from $99 and tirzepatide from $179 as cash-pay options with membership separate; other Found pages associate those amounts with insurance-linked bundles including medication. Treat these as unresolved offer differences. Ask Found to identify the applicable program and itemize every charge, then confirm coverage through the relevant plan or program rather than relying on a headline.
What the care and membership components document
Found describes an online, personalized weight-management program and says every clinician is board-certified and trained in metabolic medicine; those are provider statements, not independently verified credentials. Its compounded semaglutide process starts with a health assessment and clinician review of health history, prior efforts and personal circumstances. Prescribing depends on clinical appropriateness. The compounded tirzepatide page describes adults with obesity or overweight, a BMI of at least 25 and at least one weight-related condition; that is Found’s stated criterion, not individualized eligibility advice.
The compounded plan lists a metabolic assessment, access to weight-management clinicians, medication, one-to-one health coaching, lifestyle tools and member community access. Found also advertises Aimee, an AI health companion available around the clock. That is not a promise of continuous human clinical staffing. Its semaglutide page offers administration, storage and disposal guidance plus messaging between visits; the tirzepatide page describes monthly follow-up to review response and adjust treatment when appropriate.
Found says eligible members receive medication at home and most can start treatment within a week. That is a general treatment-start claim, not a separate guarantee of review time, dispatch or arrival. The consulted pages do not establish shipping fees, carrier, cold-chain arrangements, package supply quantity or a definitive medication-by-state availability list. They also do not confirm Spanish-language care or app access. Those practical details can change a plan’s usefulness even when its quoted price looks attractive.
A compounded price is not an approval or outcomes claim
Found describes compounded semaglutide as a once-weekly subcutaneous injection and compounded tirzepatide as a once-weekly injection. It says it works exclusively with 503A pharmacies and describes prescription-specific preparation under sterile-preparation standards. Found also says its compounded semaglutide receives third-party potency, purity and sterility testing before shipment. The reviewed material does not name the pharmacies or testing laboratory or provide certificates of analysis. These remain provider quality claims rather than independent verification.
FDA states that compounded drugs are not FDA approved and do not receive its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence or validate or condemn Found. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Approval belongs to a specific product, not a program. Found’s advertised microdosing offering should likewise not inherit evidence from approved-product studies; its complete pricing and admission criteria were not established here.
Delivery instructions are part of the practical purchase, not an optional detail. FDA advises against using an injectable GLP-1 that arrives warm or inadequately refrigerated and says to contact the provider or dispensing pharmacy. FDA has also received reports of compounded-medication measuring and administration errors, some involving hospitalization. That is not a Found-specific event rate. Request clear instructions from the prescriber or pharmacist rather than deriving a dose or injection volume from a price comparison.
Cancellation is not the same as recovering your money
Found’s membership refund language deserves clarification before purchase. It first says a full membership refund is available if cancellation occurs within three days of the original purchase or before completion of the first medical consultation. A following sentence says membership becomes nonrefundable after either event has occurred. That wording leaves uncertainty about how the two protections interact. Do not assume an unused account, an early cancellation or a large prepaid balance automatically qualifies for reimbursement.
The policy distinguishes complete medical disqualification from not receiving a preferred drug. Being disqualified from all available treatment options allows a membership refund; being ineligible for a particular GLP-1 does not if another Found option remains available. Medication and lab kits are nonrefundable and nonreturnable once dispensed or shipped, including unused items. Those boundaries matter because consultation, dispensing and shipment can create different financial consequences even before a member begins treatment.
Renewal payments are nonrefundable, and Found recommends canceling or pausing at least 48 hours before the next scheduled charge. Its policy allows up to 30 days for granted refunds; that should not be treated as a guaranteed bank-receipt date. Operational cancellation steps and refunds of unused prepayments were not fully established in the consulted documentation. Before choosing a longer term, settle those points using the questions in what happens to the money after cancellation.
Questions & answers
Does Found’s $99 semaglutide price apply to every member?
No. Found uses $99 in different contexts, including the first cycle of a new-member one-month insurance plan and the lowest longer-term insurance-associated rate. Its commercial page ties minimum pricing to 12-month prepayment. A Medicare page describes a different cash-pay arrangement. Ask which offer applies and what renews afterward.
Does the branded GLP-1 membership include Wegovy or Zepbound?
No. Found’s branded plan includes prescription services and membership, with medication billed separately. Pharmacy choice, insurance coverage and eligibility for cash-pay NovoCare or LillyDirect channels can affect that separate bill. Obtain a quote for the exact presentation and pharmacy route rather than treating membership as the treatment’s total price.
Will I need video appointments for refills?
Found says insurance members need synchronous video visits, including before each refill, with visits billed through insurance and a typical copay around $30 in addition to the plan price. Cash-pay care is asynchronous and text-based in most cases, without a separate visit copay. Confirm which format your enrollment uses.
Can I choose the pharmacy supplying compounded medication?
Found’s compounded package specifies medication filled through a pharmacy it facilitates. The documentation does not establish a member pharmacy-choice option for that bundle or name its dispensing partners. The explicit pharmacy-of-your-choice provision concerns branded prescriptions. Ask for the compounded pharmacy’s identity and contact information before dispensing.
Will Found refund me if I cannot get my preferred GLP-1?
Not necessarily. The policy says ineligibility for one medication does not qualify for a refund if other Found treatment options remain available. Complete medical disqualification is treated differently. Membership refund timing also contains ambiguous wording, while medication and lab kits become nonrefundable once dispensed or shipped. Clarify these boundaries before purchasing.
What should I obtain before accepting a longer Found plan?
Request the initial amount collected, subsequent charge dates, number of 28-day cycles, included medication and supply quantity, separate visit or laboratory charges, and treatment of unused prepaid funds. Found documents term-based rates, but its upfront-payment and four-week billing descriptions are not fully reconciled. Also confirm availability in your state and the cancellation method.
Our assessment
Found documents a broader service than prescription access alone: assessment, follow-up, coaching, app tools and multiple medication pathways. Its published introductory and term-based rates provide useful budget information, and the cash-pay versus insured-care distinction is meaningful. The weakness is reconciliation: upfront collection, four-week terms, Medicare offers and branded-drug prices do not form one consistently explained bill. A reasonable comparison should use a written, itemized quote for the exact medication and payment route, including renewal and exit terms. Found’s lowest headline price is a starting point for that inquiry, not a verified total cost or a reason by itself to choose treatment.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- Found — medication/compounded tirzepatide ↗
- Found — microdosing ↗
- Found — official website ↗
- Found — medicare weight loss ↗
- Found — medication/compounded semaglutide ↗
- Sesame / Success by Sesame — terms/offer terms v3 ↗
- Sesame / Success by Sesame — glp1 checker ↗
- Sesame / Success by Sesame — plans and pricing ↗
- Sesame / Success by Sesame — insurance ↗
- Sesame / Success by Sesame — terms/payment and billing consent ↗